Dnca Finance Sells 5,500 Shares of Danaher Corporation $DHR

Dnca Finance lessened its holdings in shares of Danaher Corporation (NYSE:DHR) by 9.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,000 shares of the conglomerate’s stock after selling 5,500 shares during the quarter. Dnca Finance’s holdings in Danaher were worth $10,272,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of DHR. National Bank of Canada FI raised its stake in shares of Danaher by 54.3% during the 1st quarter. National Bank of Canada FI now owns 628,625 shares of the conglomerate’s stock valued at $128,864,000 after purchasing an additional 221,287 shares during the period. Zions Bancorporation National Association UT purchased a new position in Danaher during the 1st quarter valued at about $667,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Danaher by 271.1% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 126,822 shares of the conglomerate’s stock valued at $25,999,000 after buying an additional 92,643 shares in the last quarter. Koa Wealth Management LLC increased its position in shares of Danaher by 13.7% during the first quarter. Koa Wealth Management LLC now owns 18,548 shares of the conglomerate’s stock valued at $3,802,000 after buying an additional 2,239 shares during the period. Finally, Johnson Financial Group LLC purchased a new stake in shares of Danaher in the first quarter worth about $343,000. Institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In related news, Director Teri List sold 3,298 shares of Danaher stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the transaction, the director owned 20,762 shares in the company, valued at $4,702,593. This trade represents a 13.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the sale, the senior vice president owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 30,248 shares of company stock valued at $6,609,663. 11.10% of the stock is currently owned by corporate insiders.

Danaher Stock Down 0.4%

DHR opened at $226.20 on Friday. The business’s fifty day simple moving average is $216.22 and its 200 day simple moving average is $204.36. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $258.23. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. The stock has a market cap of $159.78 billion, a PE ratio of 46.64, a P/E/G ratio of 4.39 and a beta of 0.89.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.71 EPS. As a group, research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s dividend payout ratio (DPR) is presently 26.39%.

Analyst Ratings Changes

DHR has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Danaher from $235.00 to $250.00 and gave the company a “buy” rating in a research note on Wednesday, October 22nd. Barclays upped their price target on shares of Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Morgan Stanley initiated coverage on Danaher in a research note on Monday, December 1st. They set an “overweight” rating and a $270.00 price objective for the company. HSBC boosted their target price on Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research report on Monday, December 1st. Finally, Royal Bank Of Canada set a $241.00 price target on Danaher in a research report on Tuesday, September 2nd. Twenty analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $245.75.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.